Skip to main content
. 2015 May 27;6(21):18590–18601. doi: 10.18632/oncotarget.4068

Figure 1. The synthesis of MPT0G157.

Figure 1

Reagents and conditions: A. 4-bromobenzenesulfonyl chlorides, pyridine, ACN, r.t.; B. t-Butyl acrylate, Pd2(dba)3, [(t-Bu)3P]BF4, K2CO3, TEA, DMF, 100–105°C; C. (i) TFA, 0°C to r.t.; (ii) EDC·HCl, HOBt, N-methylmorphine, NH2OTHP, DMF, r.t.; (iii) 10% TFA, methanol, r.t. Abbreviation: CAN, acetonitrile; DMF, dimethylformamide; K2CO3, potassium carbonate; Pd2(dba)3, tris(dibenzylideneacetone) dipalladium; [(t-Bu)3P]BF4, tris-t-tubylphosphonium tetrafluoroborate; TFA, trifluoroacetic acid; EDC, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOBt, 1-hydroxybenzotriazole; NH2OTHP, O-(tetrahydro-2H-pyran-2-yl)hydroxylamine.